Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Int J Cancer. 2011 Aug 25;131(1):30–40. doi: 10.1002/ijc.26323

Fig. 3.

Fig. 3

Regulation of pluripotency maintaining transcription factors by EGCG in pancreatic cancer stem cells. (A) Pancreatic CSCs were treated with EGCG (0-60 μM) for 36 h. At the end of incubation period, cells were harvested and the expression of Nanog, Sox-2, c-Myc and Oct-4 was measured by the q-RT-PCR. Data represent mean ± SD. *, #, or % = significantly different from respective controls, P < 0.05. (B), Nanog shRNA enhances the inhibitory effects of EGCG on CSC’s spheroid viability. Pancreatic CSCs were transduced with either scrambled shRNA or Nanog shRNA expressing lentiviral vector (pLKO.1), and cell lysates were collected and western blot analysis was performed using anti-Nanog antibody (data not shown). CSC/scrambled and CSC/Nanog shRNA were seeded as described above and treated with EGCG (0-60 μM). After 7 days, spheroids were collected and cell suspensions were prepared and viable cells were counted by trypan blue assay. Data represent mean ± SD. *, &, @, #, ** or % = significantly different from control, P < 0.05.